Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioCryst Pharmaceuticals, Inc.    BCRX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

BioCryst Pharmaceuticals, Inc. : Commentary & Reports For: (NASDAQ: BCRX), (NYSE: GST)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2013 | 07:45pm CEST

New York (April 24th, 2013) - BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) traded in the range of $1.75 and $1.97 during its latest trading session. The stock recorded the volume of 1.986 million shares. Currently, it is at $1.93, up 7.23 from its previous close. Its average daily trading volume stands at 1.085 million shares. Its MACD chart shows bullish trend and the stock is trading above its long term moving average price of $1.92. The company?s current market capitalization stands at $98.29 million.

BioCryst Pharmaceuticals stock is up 37.86 percent in the year 2013 so far while it lost 51.51 percent of its value in the past 52 weeks.

Find out if BCRX could maintain the momentum by getting the complete trend analysis report here:

http://www.monstertradingalerts.com/market-scan/?symbol=BCRX


Gastor Exploration Ltd. (NYSE: GST) stock is at $2.74, up 7.45 percent from its previous close of $2.55. The stock is up after the news of the company?s decision to sell its East Texas assets. Gastor Exploration shows bullish trend as it made the upward move with trading volume of 351,132 shares, in contrast to the average daily trading volume of 712,310 shares. Its bullish trend is further confirmed by its MACD chart and the stock is also trading above its 20 days SMA of $2.72.

Gastor Exploration stock is highly volatile with its beta at 1.57. The company?s market capitalization is at $186.18 million.

Get more news and reports on how to successfully trade GST here:

http://www.monstertradingalerts.com/market-scan/?symbol=GST

ABOUT US:

MonsterTradingAlerts.com issues momentum alerts on stocks that can provide gains to day traders. MonsterTradingAlerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. MonsterTradingAlerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals MonsterTradingAlerts.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the MonsterTradingAlerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.MonsterTradingAlerts.com

Disclosure: MonsterTradingAlerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit MonsterTradingAlerts.com website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit; http://www.monstertradingalerts.com/disclaimer/

Contact Info:
Alexander K. Neumann
Monster Trading Alerts
[email protected]
347-905-5009


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOCRYST PHARMACEUTICALS,
04/24 BioCryst to Announce First Quarter 2017 Financial Results May 4
04/12 BIOCRYST PHARMACEUTICALS, INC. (NASD : BCRX) Files An 8-K Regulation FD Disclosu..
04/12 BIOCRYST PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements an..
04/12 BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Att..
04/04 BIOCRYST PHARMACEUTICALS : Announces Mundipharma Receives Approval for Mundesine..
04/03 BIOCRYST PHARMACEUTICALS : BCRX) Down as Drug Receives Japanese Nod
04/03 BioCryst Announces Mundipharma Receives Approval for Mundesine® in Japan
03/29 BioCryst to Present at the 16th Annual Needham Healthcare Conference
03/17 BIOCRYST PHARMACEUTICALS, INC. (NASD : BCRX) Files An 8-K Entry into a Material ..
03/17 BIOCRYST PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Finan..
More news
Sector news : Bio Therapeutic Drugs
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
04/12 BioCryst expands development of BCX7353 to explore treatment of acute HAE att..
04/03 Ingrezza's Approval And Data For Shire's New Rare Disease Asset
04/03 PREMARKET GAINERS AS OF 9 : 05 am
03/26 WEEK 13 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge
03/22 Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers
Advertisement
Financials ($)
Sales 2017 24,2 M
EBIT 2017 -46,0 M
Net income 2017 -52,6 M
Finance 2017 70,0 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 18,6x
Capi. / Sales 2018 25,4x
Capitalization 521 M
More Financials
Chart BIOCRYST PHARMACEUTICALS,
Duration : Period :
BioCryst Pharmaceuticals,  Technical Analysis Chart | BCRX | US09058V1035 | 4-Traders
Full-screen chart
Technical analysis trends BIOCRYST PHARMACE...
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 8,38 $
Spread / Average Target 29%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jon P. Stonehouse President, Chief Executive Officer & Director
George B. Abercrombie Chairman
Robert Bennett Vice President-Investor Relations & Operations
Thomas R. Staab Chief Financial Officer, Treasurer, CAO & SVP
William P. Sheridan Chief Medical Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOCRYST PHARMACEUTICA..2.84%521
AMGEN, INC.11.58%120 053
CELGENE CORPORATION6.39%95 807
GILEAD SCIENCES, INC.-7.49%86 604
REGENERON PHARMACEUTIC..0.83%39 455
ACTELION LTD26.98%30 323
More Results